Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · Jul 2015
Randomized Controlled Trial Multicenter StudyApremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
Apremilast works intracellularly to regulate inflammatory mediators. ⋯ Apremilast was effective in moderate to severe plaque psoriasis.
-
J. Am. Acad. Dermatol. · Jul 2015
ReviewPatient safety in procedural dermatology: Part II. Safety related to cosmetic procedures.
Cosmetic procedures are growing in popularity and are associated with unique risks. Considering potential complications and prioritizing patient safety will help practitioners improve outcomes of elective procedures. In part II of this continuing medical education article, we provide a comprehensive review of patient safety in cosmetic procedures, including medical and legal issues surrounding the supervision and training of physician extenders.
-
J. Am. Acad. Dermatol. · Jul 2015
Tumor thickness and adnexal extension of superficial basal cell carcinoma (sBCC) as determinants of treatment failure for methylaminolevulinate (MAL)-photodynamic therapy (PDT), imiquimod, and 5-fluorouracil (FU).
Noninvasive treatments are frequently used in treatment of superficial basal cell carcinoma (sBCC) because of better cosmetic results, lower costs, and less burden on health care services when compared with surgical excision. However, probability of treatment failure is higher after noninvasive therapies and may depend on histologic tumor characteristics. ⋯ There seems to be no need to determine tumor thickness or adnexal extension in sBCC before treatment.
-
J. Am. Acad. Dermatol. · Jun 2015
Multicenter StudyPivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.
Primary analysis from the pivotal ERIVANCE BCC study resulted in approval of vismodegib, a Hedgehog pathway inhibitor indicated for treatment of adults with metastatic or locally advanced basal cell carcinoma (BCC) that has recurred after surgery or for patients who are not candidates for surgery or radiation. ⋯ The 12-month update of the study confirms the efficacy and safety of vismodegib in management of advanced BCC.
-
J. Am. Acad. Dermatol. · Jun 2015
Comparative StudyA retrospective study of 1- versus 2-cm excision margins for cutaneous malignant melanomas thicker than 2 mm.
Most guidelines recommend at least 2-cm excision margin for melanomas thicker than 2 mm. ⋯ Our study did not show any significant differences in important outcome parameters such as local or distant metastases and overall survival. A prospective study testing 1- versus 2-cm excision margin is warranted.